Context:

Pemvidutide, a dual GLP-1/glucagon receptor agonist, showed promising fibrosis improvement in adults with metabolic dysfunction-associated steatohepatitis (MASH) at phase 2, with both 1.2 mg and 1.8 mg doses outperforming placebo and a notable proportion achieving a 60% relative fibrosis reduction. In the MOMENTUM trial's 24-week interim analysis, pemvidutide also produced meaningful weight loss and favorable shifts in cardiometabolic risk factors, including total cholesterol, triglycerides, and blood pressure, compared with placebo. These results suggest potential benefits beyond weight loss, possibly reducing cardiovascular risk, but long-term safety and effects require further study. The findings come from separate phase 2 studies presented at prominent conferences, underscoring early signals of efficacy in liver and metabolic domains, while emphasizing the need for additional research.

Dive Deeper:

• Phase 2 trial in adults with metabolic dysfunction-associated steatohepatitis (MASH) and stage F2–F3 fibrosis tested two pemvidutide doses (1.2 mg and 1.8 mg) versus placebo, demonstrating greater fibrosis reduction in treated groups.

• A key efficacy signal was a higher share of participants achieving a 60% relative decrease in early and advanced fibrosis in the pemvidutide arms compared with placebo, indicating potential disease modification.

• The MOMENTUM trial’s 24-week interim analysis evaluated weight loss and cardiometabolic risk factors, showing significant reductions in weight for pemvidutide recipients versus placebo.

• Secondary outcomes in MOMENTUM included improvements in total cholesterol, triglycerides, and blood pressure, suggesting broader cardiovascular risk-factor benefits beyond weight management.

• The studies collectively position pemvidutide as a candidate addressing both liver fibrosis and metabolic-CVD risk, though researchers caution that long-term efficacy and safety data are still needed.

• Clinical context emphasizes ongoing exploration of GLP-1/glucagon receptor dual agonists for complex metabolic liver disease and obesity-related cardiometabolic risk, with future trials likely focusing on durability, safety, and real-world outcomes.

• Important considerations remain regarding long-term safety, tolerability, and the translation of fibrosis and cardiometabolic improvements into substantive clinical outcomes.